RLMD250516C2500
- 0.05
- 0.000.00%
Relmada Therapeutics Newsroom
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Hold Rating, Maintains Target Price $1
Mizuho Securities Downgrades Relmada Therapeutics(RLMD.US) to Hold Rating, Cuts Target Price to $1
Mizuho Securities Downgrades Relmada Therapeutics (RLMD) to a Hold
Relmada Therapeutics Cut to Market Perform From Outperform by Leerink Partners
Jefferies Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $13
Relmada Therapeutics Analyst Ratings
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Relmada Therapeutics Analyst Ratings
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rallybio (RLYB), Avanos Medical (AVNS) and Relmada Therapeutics (RLMD)
Relmada Therapeutics: Advancements in MDD and MASLD Programs Bolster Buy Rating
Buy Rating for Relmada Therapeutics: Efficient Management, Promising Trials and Prudent Financial Control
Analysts Offer Insights on Healthcare Companies: AngioDynamics (ANGO), Enlivex (ENLV) and Relmada Therapeutics (RLMD)
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) Gets a Buy From Mizuho Securities
Mizuho Reiterates Buy on Relmada Therapeutics, Maintains $26 Price Target
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and Relmada Therapeutics (RLMD)
SVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)